Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice

C. L. Arteaga, L. J. Kitten, E. B. Coronado, S. Jacobs, F. C. Kull, D. C. Allred, C. K. Osborne

Research output: Contribution to journalArticle

285 Citations (Scopus)

Abstract

Insulin and insulin-like growth factors (IGFs) stimulate the growth of human breast cancer cells in vitro. The type I somatomedin receptor (SR) expressed in these cells may mediate the growth effects of these peptides. We have examined the role of this receptor on human breast cancer growth with a monoclonal antibody (α-IR-3) that blocks the receptor binding domain and inhibits IGF-I-induced growth. α-IR-3 inhibited clonal growth in vitro and blocked the mitogenic effect of exogenous IGF-I in both MCF-7 and MDA-231 breast cancer cell lines. Antibody-induced blockade of the type I SR also inhibited the estrogen-independent MDA-231 cells growing in vivo in nude mice, but growth of the estrogen-dependent MCF-7 cells was unaffected. IGFs are important growth regulators of MDA-231 breast cancer cells. Blockade of this growth stimulatory pathway may provide a new treatment strategy.

Original languageEnglish (US)
Pages (from-to)1418-1423
Number of pages6
JournalJournal of Clinical Investigation
Volume84
Issue number5
DOIs
StatePublished - Jan 1 1989

Fingerprint

Somatomedin Receptors
Nude Mice
Breast Neoplasms
Growth
Somatomedins
Insulin-Like Growth Factor I
Estrogens
MCF-7 Cells
Monoclonal Antibodies
Insulin
Cell Line
Peptides
Antibodies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. / Arteaga, C. L.; Kitten, L. J.; Coronado, E. B.; Jacobs, S.; Kull, F. C.; Allred, D. C.; Osborne, C. K.

In: Journal of Clinical Investigation, Vol. 84, No. 5, 01.01.1989, p. 1418-1423.

Research output: Contribution to journalArticle

Arteaga, C. L. ; Kitten, L. J. ; Coronado, E. B. ; Jacobs, S. ; Kull, F. C. ; Allred, D. C. ; Osborne, C. K. / Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. In: Journal of Clinical Investigation. 1989 ; Vol. 84, No. 5. pp. 1418-1423.
@article{5538ac9359c94819a3a5f644f0ec5d12,
title = "Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice",
abstract = "Insulin and insulin-like growth factors (IGFs) stimulate the growth of human breast cancer cells in vitro. The type I somatomedin receptor (SR) expressed in these cells may mediate the growth effects of these peptides. We have examined the role of this receptor on human breast cancer growth with a monoclonal antibody (α-IR-3) that blocks the receptor binding domain and inhibits IGF-I-induced growth. α-IR-3 inhibited clonal growth in vitro and blocked the mitogenic effect of exogenous IGF-I in both MCF-7 and MDA-231 breast cancer cell lines. Antibody-induced blockade of the type I SR also inhibited the estrogen-independent MDA-231 cells growing in vivo in nude mice, but growth of the estrogen-dependent MCF-7 cells was unaffected. IGFs are important growth regulators of MDA-231 breast cancer cells. Blockade of this growth stimulatory pathway may provide a new treatment strategy.",
author = "Arteaga, {C. L.} and Kitten, {L. J.} and Coronado, {E. B.} and S. Jacobs and Kull, {F. C.} and Allred, {D. C.} and Osborne, {C. K.}",
year = "1989",
month = "1",
day = "1",
doi = "10.1172/JCI114315",
language = "English (US)",
volume = "84",
pages = "1418--1423",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "5",

}

TY - JOUR

T1 - Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice

AU - Arteaga, C. L.

AU - Kitten, L. J.

AU - Coronado, E. B.

AU - Jacobs, S.

AU - Kull, F. C.

AU - Allred, D. C.

AU - Osborne, C. K.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Insulin and insulin-like growth factors (IGFs) stimulate the growth of human breast cancer cells in vitro. The type I somatomedin receptor (SR) expressed in these cells may mediate the growth effects of these peptides. We have examined the role of this receptor on human breast cancer growth with a monoclonal antibody (α-IR-3) that blocks the receptor binding domain and inhibits IGF-I-induced growth. α-IR-3 inhibited clonal growth in vitro and blocked the mitogenic effect of exogenous IGF-I in both MCF-7 and MDA-231 breast cancer cell lines. Antibody-induced blockade of the type I SR also inhibited the estrogen-independent MDA-231 cells growing in vivo in nude mice, but growth of the estrogen-dependent MCF-7 cells was unaffected. IGFs are important growth regulators of MDA-231 breast cancer cells. Blockade of this growth stimulatory pathway may provide a new treatment strategy.

AB - Insulin and insulin-like growth factors (IGFs) stimulate the growth of human breast cancer cells in vitro. The type I somatomedin receptor (SR) expressed in these cells may mediate the growth effects of these peptides. We have examined the role of this receptor on human breast cancer growth with a monoclonal antibody (α-IR-3) that blocks the receptor binding domain and inhibits IGF-I-induced growth. α-IR-3 inhibited clonal growth in vitro and blocked the mitogenic effect of exogenous IGF-I in both MCF-7 and MDA-231 breast cancer cell lines. Antibody-induced blockade of the type I SR also inhibited the estrogen-independent MDA-231 cells growing in vivo in nude mice, but growth of the estrogen-dependent MCF-7 cells was unaffected. IGFs are important growth regulators of MDA-231 breast cancer cells. Blockade of this growth stimulatory pathway may provide a new treatment strategy.

UR - http://www.scopus.com/inward/record.url?scp=0024460381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024460381&partnerID=8YFLogxK

U2 - 10.1172/JCI114315

DO - 10.1172/JCI114315

M3 - Article

VL - 84

SP - 1418

EP - 1423

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 5

ER -